Skip to content

NMN for Fertility and Egg Quality: What the Evidence Shows

NMN fertility research includes human egg-culture studies. Review the findings and why oral treatment and live-birth benefits remain unproven.

By Marcus HaleLongevity Research Editor
Updated

7 min read · 12 sources

On this page

NMN (nicotinamide mononucleotide) and other NAD+ precursors are increasingly marketed to women trying to conceive — especially women in their late 30s and 40s, and women heading into IVF. The pitch is seductive: "restore your NAD+, rejuvenate your eggs." The underlying biology is real and genuinely interesting. But the honest headline, stated up front, is the one the marketing buries: the impressive fertility results are almost entirely from mice and cell-culture dishes, and there is no robust human trial showing that taking NMN or NAD+ improves egg quality, ovarian reserve, or live-birth rates. This page walks through exactly what is proven, what is preclinical, and where the evidence runs out.

A fertility hypothesis does not establish safety after conception. The NAD+ precursor pregnancy review separates egg-quality research from pregnancy and breastfeeding questions.

Affiliate partner

MadeMed

NAD+ injection & nasal spray, in 23 states

See MadeMed

Two framing points to keep throughout. First, NMN and nicotinamide riboside (NR) are sold as dietary supplements, not approved fertility drugs — none is FDA-approved to treat infertility or improve egg quality. Second, and most important for anyone trying to conceive: **NAD+ precursors are essentially unstudied in pregnancy and during conception**, so this is not a "can't hurt to try" supplement.

Why NAD+ is even in the fertility conversation

The biology that put NAD+ on the fertility map is legitimate. NAD+ is a coenzyme central to energy metabolism and DNA repair, and tissue levels decline with age across the body 1. The egg (oocyte) is one of the most energy-hungry cells in the body, and its developmental competence depends heavily on healthy mitochondria. As women age, oocyte mitochondrial function declines — and that decline is one of the best-described drivers of falling egg quality and the steep drop in fertility through the late 30s and 40s 2. Reviews of ovarian aging place NAD+ decline squarely inside that picture: less NAD+ means less fuel for the NAD+-dependent sirtuins and PARPs that oocytes rely on for energy and DNA repair 3.

So the rationale isn't fabricated. Falling NAD+ plausibly contributes to ovarian aging, and topping it up might help. The question is whether "might" has been turned into "does" — and in humans, it hasn't.

The proposed mechanism

Aging

NAD+ declines with age (human)

Less NAD+ in the ovary

Less fuel for sirtuins / PARP DNA repair

Oocyte mitochondrial dysfunction

Confirmed in human DOR ovarian tissue

Lower egg quality & fertility

Mouse findings and human egg-culture studies; oral benefit unproven

The chain is biologically plausible and the target is confirmed in human ovaries. Mouse and human egg-culture findings do not establish improved pregnancy or live birth after taking NMN.

The striking mouse data (and why it went viral)

The fertility excitement traces to one landmark animal study. Researchers gave the NAD+ precursor NMN to reproductively aged female mice and reported that NAD+ repletion restored egg quality and improved fertility outcomes — better oocyte quality, better embryo development, and more pups in aged animals 4. That result is genuinely remarkable, and it's why "NAD+ for egg quality" became a fertility-clinic talking point almost overnight.

It is not an isolated finding, either. Multiple independent animal and cell-culture studies have reported that NAD+ precursors protect oocytes from age-related decline: NR slowed the quality decline of post-ovulatory ("aged") eggs in mouse and in-vitro models 56, and a 2025 review summarizing this literature concluded that NAD+ precursors "mitigate" reproductive defects across in-vitro and in-vivo animal systems 7. As a body of preclinical work, the signal is real and consistent.

But notice the word in every one of those sentences: animal, mouse, in-vitro. That same 2025 review is blunt about the translation gap — it discusses delivery strategies that "[have] not yet been investigated in literature" and presents no human clinical evidence 7. Mouse fertility results are notoriously difficult to translate to women, and a striking effect in aged mice is a hypothesis to test in humans, not a benefit you can buy.

Human eggs in a laboratory are different from a supplement trial

There is now human-oocyte research to discuss. Calling the evidence simply “no human data” misses that distinction. A 2025 study combined chemotherapy-damage mouse experiments with laboratory work on immature eggs donated by women undergoing fertility treatment. NMN in the culture medium improved aspects of maturation and artificial activation in eggs from older women 11. Women were not assigned oral NMN, and the human experiment did not establish pregnancy or live-birth benefit.

A July 2026 conference abstract extended this laboratory question to 840 immature eggs. Rescue to a mature stage improved overall, with results varying by age and initial prognosis. Chromosome findings did not show a consistent benefit; one exploratory younger subgroup had a lower euploidy rate with NMN. That is a preliminary signal requiring validation, not proof that oral NMN causes chromosome damage. The abstract reports laboratory rescue and activation outcomes, not babies born after supplementation 12.

These findings matter because they move the science beyond mouse ovaries. They do not turn a laboratory culture concentration into a capsule dose, validate an injection program or prove that raising blood NAD+ improves an IVF outcome. Rescue of an immature egg is also a different intervention from standard care for mature eggs.

Other human observations remain indirect. Granulosa-cell proteomics in diminished ovarian reserve identified altered energy-production pathways 8. A metabolic trial in postmenopausal women tested muscle insulin sensitivity, not fertility 9. Neither answers whether taking NMN improves ovarian reserve, embryo quality, pregnancy or live birth.

What to ask before adding NMN to an IVF cycle

Ask whether the claim concerns oral supplementation, injections or an embryology-laboratory procedure. Those are different exposures. Then ask which outcome was measured: AMH, the number of eggs retrieved, maturation, chromosome status, clinical pregnancy and live birth are not interchangeable. A clinic should be able to identify the study and explain how closely its patients and protocol resemble yours.

There is no established fertility dose or evidence-based number of months to take NMN before retrieval. Animal drinking-water doses and laboratory media cannot be converted into a personal regimen. Our NMN dose-by-weight explainer explains why simple weight conversions are misleading. Do not postpone fertility assessment or change a prescribed IVF protocol while waiting for an unproven supplement to work.

Egg-quality / fertility claims readout

  • NAD+ decline contributes to ovarian agingModerate evidence

    Human mechanistic data (mitochondrial/OXPHOS disruption in DOR ovarian tissue) plus review-level support. The target is real.

  • NMN restores egg quality in aged miceStrong evidence

    As ANIMAL evidence only: multiple consistent mouse and in-vitro studies. Translation to humans is unproven.

  • NMN improves egg quality / ovarian reserve / IVF / live birth in womenNone evidence

    Human egg-culture findings are not an oral treatment trial and do not establish pregnancy or live-birth benefit.

  • NMN safety during conception / pregnancyNone evidence

    Essentially unstudied. Not a low-stakes supplement for women actively trying to conceive.

Mouse and human egg-culture research support further study. Oral fertility benefit and pregnancy safety remain unproven.

A fairer comparison: what a human-evidenced egg supplement looks like

It helps to contrast NMN with a supplement that actually has human fertility data, to show the gap. Coenzyme Q10 (CoQ10) — another mitochondrial-support compound — has been tested in randomized trials and meta-analyzed in women with diminished ovarian reserve undergoing IVF/ICSI, with reviews reporting improvements in some ovarian-response and embryo metrics 10. CoQ10's evidence is itself modest and debated, and it is not proof that NMN works — but it shows what the bar looks like: actual trials in actual IVF patients with actual reproductive endpoints. NMN has not cleared that bar; CoQ10 has at least approached it. If you're going to spend on a mitochondrial "egg quality" supplement, that difference in evidence is worth knowing.

Safety: the reason "it probably can't hurt" is the wrong frame

For most general-wellness uses, oral NMN and NR are well tolerated, with mostly mild side effects in the trials that exist 9. But fertility is a special case for two reasons:

  1. Pregnancy is unstudied. NAD+ precursors have essentially no human safety data in pregnancy or during conception. Because women using these supplements for fertility are, by definition, trying to become pregnant, you can be taking an unstudied compound at the exact moment of conception and early embryo development. That is the opposite of a low-stakes supplement.
  2. You may be spending real money on a hope. Women pursuing fertility — often while paying out of pocket for IVF — deserve to know they would be acting on preclinical (mouse) data, not proven human outcomes. The opportunity cost (money, and time on the fertility clock) is real.

Anyone considering NMN for fertility should treat it as experimental and discuss it with their reproductive endocrinologist rather than self-prescribing — particularly before or during an IVF cycle, where it could interact with a carefully managed protocol.

What this means if you are trying to conceive

NAD+ biology is a legitimate target in ovarian aging: oocyte mitochondria decline with age 2, NAD+ falls with age 1, and human ovarian tissue from women with diminished reserve shows exactly the mitochondrial disruption the theory predicts 8. The animal evidence that NMN can restore egg quality in aged mice is striking and consistent 4567. The 2025 human-oocyte study and a preliminary 2026 conference report add laboratory findings, including important limitations, but do not demonstrate reproductive benefit from taking NMN. Pregnancy safety remains unestablished. So NMN for fertility belongs firmly in the "experimental, mechanism-plausible, human-unproven" column. It is a hypothesis under study, not a buyable benefit — and not a substitute for evidence-based fertility care.

For the broader evidence picture, start with our pillar guide, NAD+ therapy: the evidence, and our honest take on whether NAD+ is really anti-aging. For the wider women's-health claims around NAD+ — menopause, energy, skin and more — see NAD+ for women. And to compare specific products on dose, form and third-party testing, see our NAD+ rankings hub and our best NMN supplements guide.

This is consumer education, not medical advice. NMN and NAD+ precursors are dietary supplements, not FDA-approved fertility treatments, and are essentially unstudied in pregnancy. If you are trying to conceive, pregnant, undergoing fertility treatment, or considering any supplement during an IVF cycle, talk to your reproductive endocrinologist first.

Frequently asked questions

Does NMN improve egg quality in humans?

NMN has been studied in isolated human eggs in a laboratory, with some maturation findings and unresolved chromosome outcomes. That is different from showing that taking NMN improves IVF success, ovarian reserve, pregnancy or live birth. No established fertility regimen follows from these studies.

Is there a human study on NMN and fertility?

Yes: a 2025 paper and a preliminary 2026 conference abstract studied human immature eggs exposed to NMN in culture. They were not trials assigning women oral NMN or injections, and did not establish improved pregnancy or live-birth outcomes from supplementation.

Is NMN safe to take while trying to conceive?

It's essentially unstudied. NAD+ precursors have almost no human safety data during conception, pregnancy, or breastfeeding. Because women take NMN for fertility precisely when trying to conceive, you can be taking an unstudied compound during early embryo development. Treat it as experimental and talk to your reproductive endocrinologist before using it, especially during an IVF cycle.

Is CoQ10 or NMN better for egg quality?

Neither is proven, but CoQ10 has more human evidence. CoQ10 has been tested in randomized trials and meta-analyzed in women with diminished ovarian reserve undergoing IVF, with some modest signals on ovarian response and embryo metrics. NMN has no comparable human reproductive trials — its human egg-culture findings are not trials of women taking a supplement. That difference in evidence is worth knowing before spending on either.

Why is there so much hype about NMN for fertility?

Because the mouse data are genuinely striking. A landmark study showed NAD+ repletion with NMN restored fertility in reproductively aged mice, and several follow-up animal studies agreed. That consistent preclinical signal got translated into clinic marketing faster than the human trials could be done — while human laboratory studies have not established a benefit from oral supplementation. Striking in mice does not mean proven in women.

References

  1. Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/
  2. Yildirim RM, Seli E (2024). Mitochondria as determinants of reproductive senescence and competence. Human Reproduction. https://pubmed.ncbi.nlm.nih.gov/39066612/
  3. Liang J, Huang F, Song Z, et al. (2023). Impact of NAD+ metabolism on ovarian aging. Immunity & Ageing. https://pubmed.ncbi.nlm.nih.gov/38041117/
  4. Bertoldo MJ, Listijono DR, Ho WJ, et al. (2020). NAD+ Repletion Rescues Female Fertility during Reproductive Aging. Cell Reports. https://pubmed.ncbi.nlm.nih.gov/32049001/
  5. Li J, et al. (2024). The NAD+ precursor nicotinamide riboside protects against postovulatory aging in vitro. Journal of Assisted Reproduction and Genetics. https://pubmed.ncbi.nlm.nih.gov/39460833/
  6. Li J, et al. (2023). Nicotinamide riboside supplementation ameliorated post-ovulatory oocyte quality decline. Reproduction. https://pubmed.ncbi.nlm.nih.gov/36269127/
  7. Arslan NP, et al. (2025). NAD+ precursors mitigate the in vitro and in vivo reproductive defects: Limitations and possible solutions. Reproductive Toxicology. https://pubmed.ncbi.nlm.nih.gov/40976508/
  8. Li X, et al. (2025). 4D quantitative proteomics of ovarian granulosa cells reveals the involvement of oxidative phosphorylation in non-elderly women with diminished ovarian reserve. Journal of Ovarian Research. https://pubmed.ncbi.nlm.nih.gov/40394695/
  9. Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. https://pubmed.ncbi.nlm.nih.gov/33888596/
  10. Lin J, et al. (2024). Clinical evidence of coenzyme Q10 pretreatment for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis. Annals of Medicine. https://pubmed.ncbi.nlm.nih.gov/39129455/
  11. Ramírez-Martín N, Buigues A, Rodríguez-Varela C, et al. (2025). Nicotinamide mononucleotide supplementation improves oocyte developmental competence in different ovarian damage conditions. American Journal of Obstetrics and Gynecology. https://pubmed.ncbi.nlm.nih.gov/39923879/
  12. Rodríguez Varela C, et al. (2026). L26/O-006 Boosting Oocyte Rescue: Nicotinamide Mononucleotide (NMN) Restores the Competence of Poor-Prognosis GV Oocytes in Aged Women. Human Reproduction (conference abstract). https://academic.oup.com/humrep/article/41/Supplement_1/deag083.006/8727141

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.